KR20230041032A - 중합체 복합 제제를 포함하는 제제 및 조성물 - Google Patents

중합체 복합 제제를 포함하는 제제 및 조성물 Download PDF

Info

Publication number
KR20230041032A
KR20230041032A KR1020237005332A KR20237005332A KR20230041032A KR 20230041032 A KR20230041032 A KR 20230041032A KR 1020237005332 A KR1020237005332 A KR 1020237005332A KR 20237005332 A KR20237005332 A KR 20237005332A KR 20230041032 A KR20230041032 A KR 20230041032A
Authority
KR
South Korea
Prior art keywords
formulation
polymer
polymer composite
kda
poloxamer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237005332A
Other languages
English (en)
Korean (ko)
Inventor
마이클 솔로몬 골드버그
폴 애덤 코노위츠
아이비 샤오위 천
Original Assignee
서지 테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 서지 테라퓨틱스, 인크. filed Critical 서지 테라퓨틱스, 인크.
Publication of KR20230041032A publication Critical patent/KR20230041032A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
KR1020237005332A 2020-07-17 2021-07-17 중합체 복합 제제를 포함하는 제제 및 조성물 Pending KR20230041032A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063053488P 2020-07-17 2020-07-17
US63/053,488 2020-07-17
US202063108861P 2020-11-02 2020-11-02
US63/108,861 2020-11-02
PCT/US2021/042110 WO2022016129A1 (en) 2020-07-17 2021-07-17 Preparations and compositions comprising polymer combination preparations

Publications (1)

Publication Number Publication Date
KR20230041032A true KR20230041032A (ko) 2023-03-23

Family

ID=79555039

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237005332A Pending KR20230041032A (ko) 2020-07-17 2021-07-17 중합체 복합 제제를 포함하는 제제 및 조성물

Country Status (10)

Country Link
US (1) US20230293427A1 (https=)
EP (1) EP4181857A4 (https=)
JP (1) JP2023534504A (https=)
KR (1) KR20230041032A (https=)
CN (1) CN116133642A (https=)
AU (1) AU2021308083A1 (https=)
BR (1) BR112023000190A2 (https=)
CA (1) CA3187174A1 (https=)
IL (1) IL299806A (https=)
WO (1) WO2022016129A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021329884A1 (en) * 2020-08-17 2023-02-16 SURGE Therapeutics, Inc. Immune modulation of myeloid derived suppressive cell function for cancer treatment
CN114617903B (zh) * 2022-03-15 2024-05-24 中国人民解放军总医院第一医学中心 一种用于血浆冻干的组合物及其应用
KR20250030440A (ko) * 2022-04-29 2025-03-05 바이오데벡 인코포레이티드 생체적합성 접착제 물질 및 사용 방법
IT202300004218A1 (it) * 2023-03-07 2024-09-07 Delim Cosmetics & Pharma S R L Composizioni termoreversibili e mucoadesive
CN116554949A (zh) * 2023-05-16 2023-08-08 广州大学 一种润滑油添加剂及其制备方法
CN117619361A (zh) * 2023-12-09 2024-03-01 中北大学 改性高岭土/包覆型高铁酸钾复合材料及其制备方法
CN120324357B (zh) * 2025-06-03 2025-10-24 上海国创医药股份有限公司 一种普瑞巴林缓释组合物及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002516617A (ja) * 1995-06-16 2002-06-04 メドロジック グローバル コーポレイション 反応性ポリマー網状構造体及びその使用法
AU6385796A (en) * 1995-06-16 1997-01-15 Medlogic Global Corporation Responsive polymer networks and methods of their use
CA2401239A1 (en) * 2000-03-03 2001-09-13 Valentis, Inc. Improved poloxamer and poloxamine compositions for nucleic acid delivery
US20060034889A1 (en) * 2004-08-16 2006-02-16 Macromed, Inc. Biodegradable diblock copolymers having reverse thermal gelation properties and methods of use thereof
CN101297973B (zh) * 2008-05-22 2010-06-09 武汉华纳生物工程有限公司 高生物粘附温敏水凝胶及其制备方法和用途
WO2010088924A1 (en) * 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
EP2520279A1 (en) * 2011-05-02 2012-11-07 TERES S.r.l. Thermoreversible gel pharamaceutical compositions for odontoiatric use
CN103055304A (zh) * 2013-01-19 2013-04-24 卓阳 一种治疗皮肤溃疡用复方温敏凝胶剂及其制备方法
US9364545B2 (en) * 2014-06-19 2016-06-14 Taipei Medical University Thermosensitive injectable hydrogel for drug delivery
CN104983722A (zh) * 2015-07-01 2015-10-21 苏州吉欧生物科技有限公司 一种皮肤祛疤修复喷膜剂的组合物及其制备方法
EP3706718A1 (en) * 2017-11-07 2020-09-16 Royal College of Surgeons in Ireland A thermo-responsive hydrogel for intratumoral administration as a treatment in solid tumor cancers
CN109820816B (zh) * 2019-02-18 2023-04-28 江苏拓弘生物科技有限公司 温度敏感性生物凝胶制剂及其应用
CN113766929A (zh) * 2019-05-02 2021-12-07 斯蒂米特公司 癌症治疗
KR102067490B1 (ko) * 2019-05-21 2020-01-20 주식회사 티젤바이오 서방성 약물전달용 온도상전이 나노 입자/하이드로젤 복합체
US12090205B2 (en) * 2019-10-28 2024-09-17 Rochal Technologies Llc Poloxamer compositions with reduced sol-gel transition temperatures and methods of reducing the sol-gel transition temperature of poloxamer compositions

Also Published As

Publication number Publication date
EP4181857A1 (en) 2023-05-24
WO2022016129A1 (en) 2022-01-20
CA3187174A1 (en) 2022-01-20
EP4181857A4 (en) 2024-08-14
JP2023534504A (ja) 2023-08-09
IL299806A (en) 2023-03-01
BR112023000190A2 (pt) 2023-04-25
CN116133642A (zh) 2023-05-16
US20230293427A1 (en) 2023-09-21
AU2021308083A1 (en) 2023-01-19

Similar Documents

Publication Publication Date Title
KR20230041032A (ko) 중합체 복합 제제를 포함하는 제제 및 조성물
AU2024267047B2 (en) Degradable hyaluronic acid hydrogels
KR20190043162A (ko) 약물 전달 조성물 및 그의 용도
KR20230079036A (ko) 암 치료를 위한 골수 유래 억제 세포 기능의 면역 조절
JP2024151337A (ja) がんの処置
US20240082236A1 (en) Cancer therapy
US20250049951A1 (en) Nucleic acid compositions and uses thereof
JP2024542575A (ja) レシキモドの固体形態及びその製剤

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230215

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240705

Comment text: Request for Examination of Application